system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: ATP Binding Cassette Transporter, Subfamily B, Member 1, Antineoplastic Agents, Blotting, Western, Cell Line, Tumor, Cell Survival, Chromatography, Liquid, Docetaxel, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Humans, Male, Prostate, Prostatic Neoplasms, Tandem Mass Spectrometry, Taxoids, Y-Box-Binding Protein 1.
user
Is differential expression of the multidrug resistance 1 ( MDR1 ) protein in prostate cancer cells independent from anticancer drug treatment and Y box binding protein 1 ( YB-1 ) activity? Context: The development of a drug-resistant phenotype is the major challenge during treatment of castration-resistant prostate cancer (PC). In solid cancer entities, one of the major contributors to chemoresistance is the multidrug resistance 1 (MDR1) protein. Believed to be involved in the induction of MDR1 expression is the presence of anticancer drugs as well as the Y box binding protein 1 (YB-1). Basal as well as drug-induced expression of MDR1 in established PC cell lines was assessed by Western blotting and mass spectrometry. Subsequently, the influence of YB-1 on MDR1 expression was examined via transient overexpression of YB-1. While LNCaP and PC-3 cells showed no detectable amounts of MDR1, the resistance factor was found to be expressed in 22Rv1 cells. Despite this difference, all three cell lines demonstrated similar growth behavior in the presence of the first-line chemotherapeutic agent docetaxel. Incubation of 22Rv1 cells with docetaxel, cabazitaxel, and abiraterone did not significantly alter MDR1 expression levels. Furthermore, overexpression of the MDR1 controlling factor YB-1 showed no impact on MDR1 expression levels.
assistant
MDR1 was detectable in the PC cell line 22Rv1. However, this study suggests that MDR1 is of less importance for drug resistance in PC cells than in other types of solid cancer. Furthermore, in contrast to YB-1 properties in other malignancies, MDR1 regulation through YB-1 seems to be unlikely. Final Decision: yes